|
Wonderful news Irene.
Genentech gave an update on status of T-DM1 agent during today's q3 earning report.
A T-DM1 phaseIII trial vs Tykerb/Xeloda in 2nd line setting MBC treatment is being prepared. Likewise a combo phaseI T-DM1 and Pertuzumab trial is being developed.
An international phaseII T-DM1 trial vs Docetaxel in 1st line setting MBC therapy has started and a stateside phaseII MBC T-DM1 trial in 3rd line setting is currently recruiting.
So it looks like Genentech is quite serious in getting this product to mqrket place.
|